IL22 and acute graft versus host disease: In preclinical models of acute GVHD, treatment with recombinant IL-22 has been shown to alleviate disease symptoms, increase the population of Lgr5+ stem cells, upregulate the expression of antimicrobial peptides such as Reg3α and Reg3γ, and improve epithelial integrity.